Biological Products, (No Diagnostic Substances) Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Biological Products, (No Diagnostic Substances)
100 results - 
- 
- 
- 
- 
- 
- - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2020-09-21 | HALO | Halozyme Therapeutics, Inc. | Labarre Michael J. | SVP, Chief Technical Officer | S - Sale | $26.91 | -12,000 | 158,800 | -7% | -$322,884 | ||||||
| D | 2020-09-17 | CHRS | Coherus Biosciences, Inc. | Anicetti Vincent R | COO | S - Sale+OE | $18.84 | -5,000 | 48,556 | -9% | -$94,216 | |||||
| DM | 2020-09-17 | TWST | Twist Bioscience Corp | Weiss Patrick | COO | S - Sale+OE | $61.83 | -14,671 | 56,699 | -21% | -$907,096 | |||||
2020-09-18 | BBI | Brickell Biotech, Inc. | McAvoy David R. | GC, CCO | P - Purchase | $0.83 | +22,526 | 81,883 | +38% | +$18,752 | ||||||
| DM | 2020-09-16 | ADPT | Adaptive Biotechnologies Corp | Robins Chad M | CEO, COB | S - Sale+OE | $45.76 | -50,040 | 1,778,180 | -3% | -$2,290,077 | |||||
| DM | 2020-09-16 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale+OE | $30.69 | -55,518 | 607,331 | -8% | -$1,704,114 | |||||
| M | 2020-09-17 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | See Remarks | S - Sale | $31.03 | -12,000 | 251,329 | -5% | -$372,324 | |||||
| D | 2020-09-16 | TWST | Twist Bioscience Corp | Green Paula | VP of HR | S - Sale+OE | $63.37 | -26,988 | 28,615 | -49% | -$1,710,100 | |||||
| D | 2020-09-16 | VIR | Vir Biotechnology, Inc. | Pang Phillip | Chief Medical Officer | S - Sale+OE | $31.90 | -12,500 | 29,777 | -30% | -$398,694 | |||||
2020-09-16 | CRSP | Crispr Therapeutics AG | Bolzon Bradley J Phd | Dir | S - Sale | $86.98 | -8,965 | 3,972,354 | 0% | -$779,777 | ||||||
| M | 2020-09-16 | MRNA | Moderna, Inc. | Bancel Stephane | CEO | S - Sale | $68.10 | -19,000 | 23,947,149 | 0% | -$1,293,810 | |||||
| AM | 2020-09-04 | TCON | Tracon Pharmaceuticals, Inc. | Ikarian Capital, LLC | Member of 10% Group, 10% | P - Purchase | $3.28 | +322,471 | 2,162,549 | +18% | +$1,057,387 | |||||
2020-09-17 | OTLK | Outlook Therapeutics, Inc. | Sukhtian Faisal Ghiath | Dir | P - Purchase | $0.67 | +10,000 | 10,000 | New | +$6,731 | ||||||
| M | 2020-09-15 | KRYS | Krystal Biotech, Inc. | Krishnan Suma | COO, 10% | S - Sale | $46.37 | -50,000 | 3,834,688 | -1% | -$2,318,629 | |||||
| D | 2020-09-15 | NSTG | Nanostring Technologies Inc | Hershberg Robert | Dir | S - Sale+OE | $43.62 | -1,500 | 1,890 | -44% | -$65,431 | |||||
| DM | 2020-09-15 | BBI | Brickell Biotech, Inc. | Veru Dennison T | Dir | P - Purchase | $0.81 | +30,000 | 1,030,840 | +3% | +$24,175 | |||||
2020-09-15 | REPL | Replimune Group, Inc. | Love Colin | COO | S - Sale | $23.97 | -15,000 | 1,021,524 | -1% | -$359,487 | ||||||
2020-09-16 | CRDF | Cardiff Oncology, Inc. | Pace Gary W | Dir | P - Purchase | $5.70 | +2,550 | 450,311 | +1% | +$14,527 | ||||||
| D | 2020-09-15 | ADPT | Adaptive Biotechnologies Corp | Hershberg Robert | Dir | S - Sale+OE | $42.58 | -2,000 | 0 | -100% | -$85,160 | |||||
| D | 2020-09-15 | ADPT | Adaptive Biotechnologies Corp | Lo Francis | Chief People Officer | S - Sale+OE | $42.58 | -2,000 | 2,500 | -44% | -$85,160 | |||||
| DM | 2020-09-14 | ADPT | Adaptive Biotechnologies Corp | Sang Charles | SVP, External Affairs | S - Sale+OE | $43.25 | -50,000 | 0 | -100% | -$2,162,500 | |||||
2020-09-14 | CRSP | Crispr Therapeutics AG | Bolzon Bradley J Phd | Dir | S - Sale | $84.89 | -1,155 | 3,981,319 | 0% | -$98,045 | ||||||
2020-09-14 | SGEN | Seattle Genetics Inc /wa | Liu Jean I | GC, EVP, Leg Affairs | S - Sale | $170.00 | -11,610 | 48,688 | -19% | -$1,973,700 | ||||||
| D | 2020-09-15 | JNCE | Jounce Therapeutics, Inc. | Duncan Barbara Gayle | Dir | S - Sale+OE | $10.00 | -10,000 | 0 | -100% | -$100,000 | |||||
| D | 2020-09-14 | BDTX | Black Diamond Therapeutics, Inc. | Hatzis-Schoch Brent | See Remarks | S - Sale+OE | $31.04 | -4,078 | 3,000 | -58% | -$126,583 | |||||
| D | 2020-09-14 | BDTX | Black Diamond Therapeutics, Inc. | Leggett Thomas | CFO | S - Sale+OE | $31.00 | -3,000 | 0 | -100% | -$93,000 | |||||
| A | 2018-03-13 | NSTG | Nanostring Technologies Inc | Young William | Dir | P - Purchase | $6.91 | +30,000 | 30,000 | New | +$207,300 | |||||
| D | 2020-09-14 | FATE | Fate Therapeutics Inc | Valamehr Bahram | Chief Development Officer | S - Sale+OE | $36.28 | -25,000 | 87,211 | -22% | -$907,024 | |||||
2020-09-14 | FATE | Fate Therapeutics Inc | Shoemaker Daniel D | Chief Scientific Officer | S - Sale | $36.30 | -25,000 | 118,091 | -17% | -$907,540 | ||||||
| M | 2020-09-04 | TCON | Tracon Pharmaceuticals, Inc. | Ikarian Capital, LLC | Member of 10% Group, 10% | P - Purchase | $3.28 | +322,471 | 2,162,549 | +18% | +$1,057,387 | |||||
2020-09-14 | OTLK | Outlook Therapeutics, Inc. | Thurman Randy H | Dir | P - Purchase | $0.62 | +10,000 | 11,875 | +533% | +$6,200 | ||||||
2020-09-14 | TARA | Protara Therapeutics, Inc. | Marshall Randall | Former 10% Owner | S - Sale | $19.40 | -2,554 | 585,600 | 0% | -$49,541 | ||||||
2020-09-11 | STRO | Sutro Biopharma, Inc. | Freund John Gordon | Dir | S - Sale | $10.00 | -500,000 | 960,053 | -34% | -$5,000,000 | ||||||
2020-09-11 | IMVT | Immunovant, Inc. | Butchko Julia G. | Chief Dev., Tech. Officer | P - Purchase | $38.17 | +5,000 | 5,000 | New | +$190,850 | ||||||
| D | 2020-09-14 | MRNA | Moderna, Inc. | Zaks Tal Zvi | Chief Medical Officer | S - Sale+OE | $62.66 | -20,034 | 0 | -100% | -$1,255,321 | |||||
| D | 2020-09-14 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale+OE | $61.42 | -20,000 | 1,940,646 | -1% | -$1,228,468 | |||||
| D | 2020-09-11 | XLRN | Acceleron Pharma Inc | McCourt Thomas A | Dir | S - Sale+OE | $90.39 | -23,272 | 4,422 | -84% | -$2,103,466 | |||||
2020-09-11 | MRNA | Moderna, Inc. | Bancel Stephane | CEO | S - Sale | $58.42 | -11,046 | 23,967,149 | 0% | -$645,259 | ||||||
2020-09-10 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Officer | S - Sale | $31.00 | -3,689 | 190,141 | -2% | -$114,359 | ||||||
2020-09-11 | HALO | Halozyme Therapeutics, Inc. | Matsui Connie | Dir | S - Sale | $27.06 | -32,000 | 208,753 | -13% | -$865,792 | ||||||
2020-09-10 | TARA | Protara Therapeutics, Inc. | Marshall Randall | 10% | S - Sale | $18.00 | -239 | 588,154 | 0% | -$4,302 | ||||||
2020-09-10 | TCON | Tracon Pharmaceuticals, Inc. | Wiggins Mark C | Chief Business Officer | P - Purchase | $4.14 | +7,000 | 12,350 | +131% | +$28,953 | ||||||
2020-09-11 | ADMA | Adma Biologics, Inc. | Demski Martha J | Dir | P - Purchase | $2.29 | +2,200 | 4,200 | +110% | +$5,038 | ||||||
| D | 2020-09-10 | RGEN | Repligen Corp | Hunt Anthony | CEO | S - Sale+OE | $148.20 | -45,351 | 233,327 | -16% | -$6,721,018 | |||||
2020-09-10 | CRSP | Crispr Therapeutics AG | Bolzon Bradley J Phd | Dir | S - Sale | $85.36 | -22,845 | 1,895,354 | -1% | -$1,949,996 | ||||||
| DM | 2020-09-10 | ADPT | Adaptive Biotechnologies Corp | Cohen Chad M | CFO | S - Sale+OE | $40.00 | -10,000 | 1,000 | -91% | -$400,000 | |||||
| DM | 2020-09-10 | ADPT | Adaptive Biotechnologies Corp | Baldo Lance | Chief Medical Officer | S - Sale+OE | $40.00 | -4,167 | 0 | -100% | -$166,680 | |||||
| DM | 2020-09-09 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale+OE | $29.02 | -7,043 | 619,331 | -1% | -$204,419 | |||||
| D | 2020-09-09 | SGEN | Seattle Genetics Inc /wa | Himes Vaughn B | Chief Technical Officer | S - Sale+OE | $147.55 | -8,000 | 186,829 | -4% | -$1,180,385 | |||||
2020-09-10 | NERV | Minerva Neurosciences, Inc. | Van Heek G Jan | Dir | P - Purchase | $2.97 | +7,000 | 20,333 | +53% | +$20,790 | ||||||
| D | 2020-09-08 | NSTG | Nanostring Technologies Inc | Malloy Kirk | Dir | S - Sale+OE | $36.61 | -3,400 | 990 | -77% | -$124,474 | |||||
| D | 2020-09-09 | NSTG | Nanostring Technologies Inc | Gray R Bradley | Pres, CEO | S - Sale+OE | $38.85 | -37,951 | 111,686 | -25% | -$1,474,512 | |||||
| D | 2020-09-09 | TWST | Twist Bioscience Corp | Thorburn James M | CFO | S - Sale+OE | $65.96 | -20,000 | 51,719 | -28% | -$1,319,124 | |||||
| M | 2020-09-09 | MRNA | Moderna, Inc. | Bancel Stephane | CEO | S - Sale | $56.56 | -26,030 | 16,213,315 | 0% | -$1,472,319 | |||||
| M | 2020-09-09 | CBGL | Cannabis Global, Inc. | Ghs Investments, LLC | 10% | S - Sale | $0.10 | -76,860 | 3,090,453 | -2% | -$7,479 | |||||
2020-09-10 | ADMA | Adma Biologics, Inc. | Grossman Jerrold B | Dir | P - Purchase | $2.22 | +5,000 | 253,571 | +2% | +$11,100 | ||||||
| D | 2020-09-08 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale+OE | $29.05 | -1,800 | 623,559 | 0% | -$52,286 | |||||
| DM | 2020-09-08 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | See Remarks | S - Sale+OE | $29.06 | -4,042 | 263,329 | -2% | -$117,467 | |||||
| D | 2020-09-08 | MRNA | Moderna, Inc. | Zaks Tal Zvi | Chief Medical Officer | S - Sale+OE | $56.20 | -26,467 | 0 | -100% | -$1,487,355 | |||||
| D | 2020-09-08 | VIR | Vir Biotechnology, Inc. | Virgin Herbert | EVP, Research, CSO | S - Sale+OE | $29.99 | -3,805 | 20,000 | -16% | -$114,098 | |||||
| D | 2020-08-25 | VIR | Vir Biotechnology, Inc. | Virgin Herbert | EVP, Research, CSO | S - Sale+OE | $42.92 | -5,560 | 20,000 | -22% | -$238,632 | |||||
2020-09-08 | LJPC | La Jolla Pharmaceutical Co | Ramsay David A | Dir | P - Purchase | $3.83 | +1,000 | 48,000 | +2% | +$3,830 | ||||||
| M | 2020-09-08 | TARA | Protara Therapeutics, Inc. | Marshall Randall | 10% | S - Sale | $18.73 | -13,330 | 588,393 | -2% | -$249,632 | |||||
2020-09-09 | XFOR | X4 Pharmaceuticals, Inc | Skerlj Renato | Chief Scientific Officer | S - Sale | $8.05 | -5,834 | 42,076 | -12% | -$46,964 | ||||||
2020-09-09 | XFOR | X4 Pharmaceuticals, Inc | Ragan Paula | Pres, CEO | S - Sale | $8.04 | -8,840 | 287,323 | -3% | -$71,074 | ||||||
2020-09-09 | XFOR | X4 Pharmaceuticals, Inc | Meisner Derek M | GC | S - Sale | $8.05 | -8,334 | 16,666 | -33% | -$67,089 | ||||||
2020-09-08 | ADMA | Adma Biologics, Inc. | Mond James | EVP, CSO, CMO | P - Purchase | $2.20 | +4,000 | 73,174 | +6% | +$8,800 | ||||||
2020-09-08 | ADMA | Adma Biologics, Inc. | Grossman Adam S | Pres, CEO | P - Purchase | $2.24 | +4,000 | 1,635,499 | 0% | +$8,960 | ||||||
| D | 2020-09-08 | ADPT | Adaptive Biotechnologies Corp | Cohen Chad M | CFO | S - Sale+OE | $36.17 | -20,000 | 1,000 | -95% | -$723,400 | |||||
| D | 2020-09-08 | ADPT | Adaptive Biotechnologies Corp | Baldo Lance | Chief Medical Officer | S - Sale+OE | $36.17 | -2,083 | 0 | -100% | -$75,342 | |||||
| M | 2020-09-04 | LJPC | La Jolla Pharmaceutical Co | Tang Kevin C | Dir, 10% | P - Purchase | $3.94 | +278,369 | 9,405,490 | +3% | +$1,096,829 | |||||
| DM | 2020-09-04 | TCON | Tracon Pharmaceuticals, Inc. | Opaleye Management Inc. | 10% | P - Purchase | $3.38 | +56,558 | 1,934,704 | +3% | +$190,902 | |||||
| M | 2020-09-04 | TWST | Twist Bioscience Corp | Leproust Emily M. | Pres, CEO | S - Sale | $62.98 | -100,000 | 607,698 | -14% | -$6,298,310 | |||||
| DM | 2020-09-04 | TWST | Twist Bioscience Corp | Thorburn James M | CFO | S - Sale+OE | $63.23 | -100,000 | 51,719 | -66% | -$6,323,099 | |||||
2020-09-08 | XLRN | Acceleron Pharma Inc | Veness Adam M | SVP, GC, Sec. | S - Sale | $89.50 | -2,000 | 19,161 | -9% | -$179,004 | ||||||
2020-09-04 | CBGL | Cannabis Global, Inc. | Ghs Investments, LLC | 10% | S - Sale | $0.13 | -16,500 | 3,167,313 | -1% | -$2,066 | ||||||
2020-09-04 | TCON | Tracon Pharmaceuticals, Inc. | Theuer Charles | Pres, CEO | P - Purchase | $2.58 | +10,000 | 181,882 | +6% | +$25,750 | ||||||
| M | 2020-09-03 | KOD | Kodiak Sciences Inc. | Baker Bros. Advisors LP | Dir, 10% | P - Purchase | $47.43 | +322,979 | 11,090,409 | +3% | +$15,318,311 | |||||
2020-09-04 | MRNA | Moderna, Inc. | Bancel Stephane | CEO | S - Sale | $61.87 | -11,046 | 24,005,225 | 0% | -$683,459 | ||||||
2020-09-03 | BLUE | Bluebird Bio, Inc. | Finger Alison Cecily | Chief Commercial Officer | S - Sale | $58.60 | -35 | 27,063 | 0% | -$2,051 | ||||||
2020-09-03 | BLUE | Bluebird Bio, Inc. | Smith-Farrell Joanne | Chief Business Officer | S - Sale | $58.60 | -36 | 22,051 | 0% | -$2,110 | ||||||
2020-09-03 | BLUE | Bluebird Bio, Inc. | Cole Jason | COO and | S - Sale | $58.60 | -36 | 35,337 | 0% | -$2,110 | ||||||
2020-09-03 | BLUE | Bluebird Bio, Inc. | Gregory Philip D | Chief Scientific Officer | S - Sale | $58.60 | -58 | 35,984 | 0% | -$3,399 | ||||||
2020-09-03 | BLUE | Bluebird Bio, Inc. | Davidson David | Chief Medical Officer | S - Sale | $58.60 | -41 | 39,767 | 0% | -$2,403 | ||||||
2020-09-03 | BLUE | Bluebird Bio, Inc. | Leschly Nick | Pres, CEO | S - Sale | $58.60 | -431 | 267,728 | 0% | -$25,257 | ||||||
| DM | 2020-09-02 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale+OE | $29.05 | -3,100 | 624,459 | 0% | -$90,058 | |||||
2020-09-04 | IMVT | Immunovant, Inc. | Roivant Sciences Ltd. | 10% | P - Purchase | $33.00 | +380,000 | 47,593,419 | +1% | +$12,540,000 | ||||||
| D | 2020-09-03 | BDTX | Black Diamond Therapeutics, Inc. | Roberts Christopher D. | Chief Scientific Officer | S - Sale+OE | $29.59 | -2,500 | 0 | -100% | -$73,987 | |||||
| M | 2020-09-02 | TARA | Protara Therapeutics, Inc. | Marshall Randall | 10% | S - Sale | $20.58 | -259 | 601,723 | 0% | -$5,331 | |||||
| D | 2020-09-03 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale+OE | $65.65 | -10,000 | 1,950,646 | -1% | -$656,500 | |||||
2020-09-03 | MRNA | Moderna, Inc. | Bancel Stephane | CEO | S - Sale | $65.65 | -10,000 | 24,016,271 | 0% | -$656,500 | ||||||
2020-09-02 | PTE | Polarityte, Inc. | Seaburg David B | CEO | S - Sale | $1.13 | -5,600 | 959,338 | -1% | -$6,306 | ||||||
| M | 2020-09-02 | CBGL | Cannabis Global, Inc. | Ghs Investments, LLC | 10% | S - Sale | $0.13 | -41,617 | 3,183,813 | -1% | -$5,211 | |||||
| M | 2020-08-28 | LIFE | Atyr Pharma Inc | Clarke John K | Dir | S - Sale | $4.01 | -7,360 | 118,075 | -6% | -$29,513 | |||||
| D | 2020-09-01 | CRSP | Crispr Therapeutics AG | Bolzon Bradley J Phd | Dir | S - Sale+OE | $92.51 | -60,000 | 4,163,064 | -1% | -$5,550,644 | |||||
| DM | 2020-09-01 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | See Remarks | S - Sale+OE | $27.92 | -12,226 | 265,769 | -4% | -$341,395 | |||||
| DM | 2020-09-01 | TCON | Tracon Pharmaceuticals, Inc. | Opaleye Management Inc. | 10% | P - Purchase | $2.28 | +159,800 | 1,878,146 | +9% | +$363,825 | |||||
2020-09-02 | XFOR | X4 Pharmaceuticals, Inc | Ragan Paula | Pres, CEO | S - Sale | $7.99 | -2,400 | 296,163 | -1% | -$19,176 | ||||||
| D | 2020-09-01 | CRSP | Crispr Therapeutics AG | Tomsicek Michael John | CFO | S - Sale+OE | $92.26 | -12,000 | 410 | -97% | -$1,107,068 | |||||
| D | 2020-09-01 | CRSP | Crispr Therapeutics AG | Novak Rodger | Pres | S - Sale+OE | $92.62 | -25,000 | 648,007 | -4% | -$2,315,578 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |